COMPANY

Monopar Therapeutics

Keywords: oncology Wilson disease Bladder Cancer Urothelial Carcinoma Triple-negative Breast Cancer Lung Cancer Colorectal Cancer Gastric Cancer Ovarian Cancer Pancreatic Cancer Solid Tumor Cancer uPAR-positive Solid Tumor Urokinase Plasminogen Activator Receptor-positive Solid Tumor Advanced Soft-tissue Sarcoma Chemoradiotherapy-Induced Severe Oral Mucositis MNPR-101-PCTA-177Lu MNPR-101-DFO*-89Zr Camsirubicin

Profile checked Oct 10, 2026

$194.2MRaised (2 yrs)6Trials (company is sponsor)

Timeline

Sep 24, 2025 Raise Follow-on offering: $135M (total, as published), announced Sep 24, 2025. Source: company release on GlobeNewswire. source ↗
Dec 20, 2024 Raise Follow-on offering: $40M (total, as published), announced Dec 20, 2024. Source: company release on GlobeNewswire. source ↗
Oct 30, 2024 Raise Follow-on offering: $19.2M (total, as published), announced Oct 30, 2024. Source: company release on GlobeNewswire. source ↗
Oct 8, 2024 Trial start Phase 1: Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors source ↗
May 30, 2024 Trial start Phase 1: Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors source ↗
Sep 22, 2021 Trial start Phase 1: Camsirubicin + Pegfilgrastim to Determine MTD in ASTS source ↗
Feb 11, 2021 Trial start Phase 2/Phase 3: Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 1 · Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors · NCT06337084
2027-01 (ESTIMATED) · Phase 1 · Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors · NCT06617169

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $194.2M. Last 2 years.

Sep 24, 2025 Follow-on offering: $135M (total, as published), announced Sep 24, 2025. Source: company release on GlobeNewswire. source ↗
Dec 20, 2024 Follow-on offering: $40M (total, as published), announced Dec 20, 2024. Source: company release on GlobeNewswire. source ↗
Oct 30, 2024 Follow-on offering: $19.2M (total, as published), announced Oct 30, 2024. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT06980519	MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer	Not listed	Temporarily not available	Not listed	Not listed
NCT06980506	MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer	Not listed	Temporarily not available	Not listed	Not listed
NCT06617169	Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors	Phase 1	Active, not recruiting	Oct 8, 2024	2027-01 (estimated)
NCT06337084	Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors	Phase 1	Active, not recruiting	May 30, 2024	2026-12 (estimated)
NCT05043649	Camsirubicin + Pegfilgrastim to Determine MTD in ASTS	Phase 1	Terminated	Sep 22, 2021	Oct 31, 2023 (actual)
NCT04648020	Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.	Phase 2/Phase 3	Terminated	Feb 11, 2021	May 14, 2023 (actual)